CN Patent

CN105497023B — 一种沙格列汀药物制剂

Assigned to Beijing Fuyuan Pharmaceutical Co ltd · Expires 2021-05-25 · 5y expired

What this patent protects

本发明开发出一种新的沙格列汀药物制剂，该制剂由沙格列汀、酸性颗粒和润滑剂组成，其中酸性颗粒由填充剂和酸制成。该药物制剂可以有效克服沙格列汀性质不稳定的缺陷，减少活性成分沙格列汀的降解，保证疗效。

USPTO Abstract

本发明开发出一种新的沙格列汀药物制剂，该制剂由沙格列汀、酸性颗粒和润滑剂组成，其中酸性颗粒由填充剂和酸制成。该药物制剂可以有效克服沙格列汀性质不稳定的缺陷，减少活性成分沙格列汀的降解，保证疗效。

Drugs covered by this patent

saxagliptin-hydrochloride (SAXAGLIPTIN HYDROCHLORIDE)

Patent Metadata

Patent number: CN105497023B
Jurisdiction: CN
Classification: —
Expires: 2021-05-25
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Fuyuan Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.